Table 4.

Associations of ejection fraction clinical cut points with incident heart failure and death in the Chronic Renal Insufficiency Cohort participants without baseline heart failure

Ejection Fraction, %N (Events)N (Participants)RateHR (95% CI)
Model 1Model 2Model 3
Heart failure
 >6561935.40.39 (0.17 to 0.89)0.41 (0.18 to 0.94)0.38 (0.16 to 0.94)
 50–65177220515.1ReferenceReferenceReference
 35–505243324.31.52 (1.09 to 2.13)1.59 (1.14 to 2.24)1.57 (1.12 to 2.21)
 <35134866.55.02 (2.76 to 9.14)5.2 (2.78 to 9.72)3.67 (1.93 to 6.99)
 Linear trend P value<0.001<0.001<0.001
Death
 >651819314.40.7 (0.43 to 1.13)0.72 (0.45 to 1.17)0.63 (0.37 to 1.07)
 50–65336220524.0ReferenceReferenceReference
 35–507343326.91.02 (0.77 to 1.34)1.03 (0.78 to 1.36)0.94 (0.71 to 1.24)
 <35204876.82.38 (1.48 to 3.84)2.49 (1.53 to 4.07)0.94 (0.71 to 1.24)
 Linear trend P value0.004<0.010.04
  • Model 1: age, race, study site, diabetes, cardiovascular disease, tobacco, alcohol use, log(24-hour proteinuria), eGFR (Chronic Renal Insufficiency Cohort equation), systolic BP, diastolic BP, body mass index, LDL, HDL, aldosterone antagonists, angiotensin–converting enzyme inhibitors, angiotensin receptor blockers, diuretics, β-blockers, phosphate, and hemoglobin. Model 2: model 1 plus log(parathyroid hormone), log(fibroblast growth factor-23), aspirin, and statin. Model 3: model 2 plus log(B–type natriuretic peptide) and log(high–sensitivity troponin T). HR, hazard ratio; 95% CI, 95% confidence interval.